Given that a majority of patients are diagnosed at an advanced stage, it would be essential to investigate the effect of HGF/c-MET inhibition in combination with gemcitabine in a model of advanced pancreatic cancer. The gene discussed is HGF; the disease is pancreatic neoplasm.